SCHEMBL2360413

SCHEMBL2360413

COc1ccc(-c2noc(-c3cc(C)[nH]n3)n2)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
MAPT P10636 5/20 0.49
POLB P06746 1/20 0.49
TP53 P04637 4/20 0.48
SMN1; SMN2 Q16637 6/20 0.47
KDM4E B2RXH2 4/20 0.47
NPC1 O15118 4/20 0.47
TSHR P16473 3/20 0.47
HSD17B10 Q99714 3/20 0.47
RAB9A P51151 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NFKB1 P19838 1/20 0.47
MAPK1 P28482 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
PPARG P37231 1/20 0.46
NCOA2 Q15596 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2360587 0.87 S1PR1 (0.43) HTTMAPTPOLBTP53NPSR1
SCHEMBL16682102 0.82 NPC1 (0.54) MAPTPOLBSMN1; SMN2KDM4ENPC1
SCHEMBL2360362 0.81 MAPT (0.71) MAPTPOLBTP53SMN1; SMN2KDM4E
SCHEMBL2640806 0.79 S1PR1 (0.48) HTTMAPTPOLBTP53NPSR1
SCHEMBL12185175 0.79 MAPT (0.42) MAPTPOLBTP53SMN1; SMN2NPC1
SCHEMBL2360912 0.77 MAPT (0.45) MAPTPOLBTP53SMN1; SMN2NPC1
SCHEMBL12185622 0.76 ALOX5AP (0.44) MAPTPOLBTP53S1PR1
SCHEMBL2640808 0.76 MAPT (0.52) MAPTPOLBTP53SMN1; SMN2NPC1
SCHEMBL2358668 0.76 MAPT (0.51) MAPTPOLBTP53SMN1; SMN2NPC1
SCHEMBL2640845 0.75 MAPT (0.49) MAPTPOLBTP53SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301122-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-08 US disclosed
US-20110301122-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-08 US disclosed
EP-2356112-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-17 EP disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301122-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS HIF1AN, HIF1A, VHL HTT 1930/4885MAPT 4432/4885POLB 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.